Clinical trials
ITP clinical trials
Below are recruiting itp clinical trials, each written for real people, not researchers. We’re tracking 66 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07194850RecruitingPhase 2/Phase 3
Study of Efgartigimod for teens with chronic ITP
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
BordeauxAges 12–17 - NCT07043946RecruitingPhase 1/Phase 2
Budoprutug for immune thrombocytopenia
This trial tests a new drug called budoprutug for people with immune thrombocytopenia (ITP), a condition where your immune system attacks your own platelets, causing low counts. The study aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
PlovdivAges 18 years+ - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Fayetteville, ArkansasAges 18 years+ - NCT06929299RecruitingPhase 1/Phase 2
Testing STSA-1301 for immune thrombocytopenia (ITP)
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
Bengbu, AnhuiAges 18–75 - NCT06568913Recruiting
TPO-RA medicines for children with long-term ITP
This study looks at how well certain medicines (called thrombopoietin receptor agonists, or TPO-RAs) work for children with long-term ITP that did not improve with steroids. The goal is to see if these medicines can help raise platelet counts and reduce bleeding.
SohagAges 1–18 - NCT07059000RecruitingPhase 3
Study of a drug for adults with chronic ITP
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
Los Angeles, CaliforniaAges 18–70 - NCT04518475RecruitingPhase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
TianjinAges 18–60 - NCT04968899RecruitingPhase 3
IgG IV plus prednisone versus high-dose dexamethasone for ITP
This Phase 3 study compares two ways of treating immune thrombocytopenia (ITP) to raise blood platelet counts and reduce bleeding. It tests whether IgG given through a vein plus prednisone works better (or safer) than high-dose dexamethasone.
CréteilAges 18–80 - NCT06352281RecruitingPhase 1/Phase 2
CAR-T cell therapy for chronic or hard-to-treat ITP
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
Kunming, YunnanAges 8–75 - NCT06880081RecruitingPhase 1
A study of PN20 for adults with immune thrombocytopenia
This trial tests a new drug called PN20 for adults with a long-term low platelet condition called immune thrombocytopenia (ITP). It aims to see if the drug can safely raise platelet counts for people who have not gotten better with other treatments.
Guiyang, GuizhouAges 18–65 - NCT06919341Recruiting
Spanish immune thrombocytopenia registry
This study collects data from people with immune thrombocytopenia (a condition where the immune system destroys platelets, causing low blood counts). It aims to better understand and track the disease over time.
A Coruña, A CoruñaAges 2 months+ - NCT07133659RecruitingPhase 4
New starting dose of avatrombopag for immune thrombocytopenia
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
BaghdadAges 18 years+ - NCT07294365RecruitingPhase 2
Study of DZD8586 for adults with chronic ITP
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT07612319Recruiting
Romiplostim injection for treatment-resistant ITP
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
Suzhou, JiangsuAges 18 years+ - NCT06838949RecruitingPhase 2
Herombopag for ITP in patients age 60 and older
This trial tests a medication called Herombopag to raise platelet counts in adults aged 60 or older with immune thrombocytopenia (ITP). The goal is to see if it is safe and effective for this age group.
TianjinAges 60 years+ - NCT06948318RecruitingPhase 3
Follow-up study of mezagitamab for chronic ITP
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
Hot Springs, ArkansasAges 18 years+ - NCT06722235RecruitingPhase 3
Mezagitamab for chronic ITP that hasn't responded to standard treatments
This study tests a new medicine called mezagitamab for adults with chronic ITP (low platelets for at least a year) who have not responded well to standard treatments. It aims to see if mezagitamab can safely raise platelet counts.
Hot Springs, ArkansasAges 18 years+ - NCT07068126Recruiting
New treatment for kids with lasting ITP
This trial tests a new approach for children ages 1 to 10 who have had ITP for 3–12 months. It aims to find a better way to manage the condition and improve platelet counts.
AsyutAges 1–10 - NCT05520892RecruitingPhase 4
IVIG dose options for newly diagnosed childhood ITP
This study compares two intravenous (IV) IgG treatment regimens for children newly diagnosed with immune thrombocytopenia (ITP). It aims to find a regimen that works well and is safe for raising low platelet counts.
Fuzhou, FujianAges 4 weeks–14 years - NCT04890041Recruiting
Testing TPO medicines for immune low platelets in teens
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT06479304Recruiting
Hydroxychloroquine plus prednisone for ANA-positive ITP
This study tests whether a combination of hydroxychloroquine (HCQ) and prednisone (a steroid) is safe and effective for treating immune thrombocytopenia (ITP) in people who have a positive ANA blood test. It may be an option for those with low platelets and bleeding risk.
Shanghai, Shanghai MunicipalityAges 15–99 - NCT06479317Recruiting
Combining hydroxychloroquine and dexamethasone for ITP with positive ANA
This trial tests if adding hydroxychloroquine (HCQ) to the steroid dexamethasone (DEX) works better than dexamethasone alone for adults with immune thrombocytopenia (ITP) who have a positive antinuclear antibody (ANA) blood test. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Shanghai, Shanghai MunicipalityAges 15–75 - NCT06479291Recruiting
HCQ plus TPO-RA for ANA positive ITP
This trial tests if combining two medicines (HCQ and a TPO-RA) can help people with a type of low platelet count called ITP who also have a positive ANA blood test. The goal is to see if this combination works better than standard treatments.
Shanghai, Shanghai MunicipalityAges 15–99 - NCT06371417RecruitingPhase 1
Testing RAY121 for several immune diseases (RAINBOW trial)
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
Orange, CaliforniaAges 18–85
Hear when a new ITP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for itp?
- Yes. Clin2 currently lists 66 recruiting itp studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a itp trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a itp trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.